Healthcare / BiotechnologyNasdaqGS
$9.24
-0.35 (-3.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-167.0M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$737M
P/E
N/A
•EV/EBITDA
N/A
•ROE
50.5%
↑Gross Margin
87.1%
↑Debt/Equity
-0.48
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-95.4%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $175.1M · net income $-221.2M · FCF $-167.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $175.1M | $175.1M | $55.3M | $682000.00 | — | — | — | — | — |
| Net Income | $-221.2M | $-221.2M | $-334.3M | $-201.6M | $-197.7M | $-143.9M | $-129.1M | $-255.1M | $-1.3M |
| EBITDA | $-152.5M | $-152.5M | $-261.5M | $-159.0M | $-169.8M | $-134.6M | $-125.3M | $-106.2M | — |
| EPS | -3.03 | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 | — | — | — |
| Gross Margin | 87.1% | 87.1% | 85.6% | 75.5% | — | — | — | — | — |
| Operating Margin | -91.4% | -91.4% | -502.2% | -24532.6% | — | — | — | — | — |
| Net Margin | -126.3% | -126.3% | -605.1% | -29558.9% | — | — | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | -0.48 | -0.48 | -0.80 | -1.91 | -1.30 | 1.24 | 0.20 | 0.10 | — |
| Current Ratio | 2.21 | 2.21 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-167.0M | $-167.0M | $-266.9M | $-139.2M | $-147.6M | $-148.8M | $-70.7M | $-36.6M | — |
| Returns | |||||||||
| ROE | 50.5% | 50.5% | 131.8% | 277.1% | 264.3% | -199.4% | -66.4% | -111.9% | 100.2% |
| Growth & Yield | |||||||||
| Revenue Growth | 216.9% | 216.9% | 8001.5% | — | — | — | — | — | — |
| EPS Growth | 42.7% | 42.7% | -34.6% | 22.2% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+117.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.29 → -3.03
Residual
+117.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.